Table 1.

Patient distribution according to SBP and albuminuria reduction at month 6 from baselinea

Albuminuria ReductionSBP ReductionTotal (n [%])
<−15 mmHg (n [%])−15 to 0 mmHg (n [%])0 to 15 mmHg (n [%])≥15 mmHg (n [%])
Losartan-treated patients
    <−30%33 (4.6)31 (4.3)41 (5.7)23 (3.2)128 (17.9)
    −30 to 0%14 (2.0)27 (3.8)29 (4.1)24 (3.4)94 (13.1)
    0 to 30%23 (3.2)36 (5.0)64 (9.0)38 (5.3)161 (22.5)
    ≥30%40 (5.6)59 (8.5)114 (15.9)119 (16.6)332 (46.4)
    total110 (15.4)153 (21.4)248 (34.7)204 (28.5)715 (100)
Placebo-treated patients
    <−30%63 (8.8)69 (9.7)77 (10.8)47 (6.6)256 (35.9)
    −30 to 0%26 (3.6)43 (6.0)45 (6.3)26 (3.6)140 (19.6)
    0 to 30%25 (3.5)50 (7.0)48 (6.7)42 (5.9)165 (23.1)
    ≥30%21 (2.9)30 (4.2)45 (6.3)56 (7.9)152 (21.3)
    total135 (18.9)192 (26.9)215 (30.2)171 (24.0)713 (100)
  • a Categories with discordant effects on systolic BP (SBP) and albuminuria are in boldface type.